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A B S T R A C T
Intracellular Ca2+ and cAMP typically cause opposing eﬀects on airway smooth muscle contraction. Receptors
that stimulate these pathways are therapeutic targets in asthma and chronic obstructive pulmonary disease.
However, the interactions between diﬀerent G protein-coupled receptors (GPCRs) that evoke cAMP and Ca2+
signals in human bronchial airway smooth muscle cells (hBASMCs) are poorly understood. We measured Ca2+
signals in cultures of ﬂuo-4-loaded hBASMCs alongside measurements of intracellular cAMP using mass spec-
trometry or [3H]-adenine labeling. Interactions between the signaling pathways were examined using selective
ligands of GPCRs, and inhibitors of Ca2+ and cAMP signaling pathways. Histamine stimulated Ca2+ release
through inositol 1,4,5-trisphosphate (IP3) receptors in hBASMCs. β2-adrenoceptors, through cAMP and protein
kinase A (PKA), substantially inhibited histamine-evoked Ca2+ signals. Responses to other Ca2+-mobilizing
stimuli were unaﬀected by cAMP (carbachol and bradykinin) or minimally aﬀected (lysophosphatidic acid).
Prostaglandin E2 (PGE2), through EP2 and EP4 receptors, stimulated formation of cAMP and inhibited histamine-
evoked Ca2+ signals. There was no consistent relationship between the inhibition of Ca2+ signals and the
amounts of intracellular cAMP produced by diﬀerent timuli. We conclude that β-adrenoceptors, EP2 and EP4
receptors, through cAMP and PKA, selectively inhibit Ca2+ signals evoked by histamine in hBASMCs, suggesting
that PKA inhibits an early step in H1 receptor signaling. Local delivery of cAMP within hyperactive signaling
junctions mediates the inhibition.
1. Introduction
Bronchial asthma and chronic obstructive pulmonary disease
(COPD) are associated with inﬂammation, hyper-responsiveness and
airway obstruction leading to restricted airﬂow. Although the nature of
the inﬂammation and disease progression [1–3] diﬀer for asthma and
COPD, a major therapeutic target for both diseases is airway smooth
muscle (ASM). Enhanced contractile activity and/or proliferation of
ASM provoked by increased levels of acetylcholine, histamine, brady-
kinin or cytokines; by increased responsiveness to acetylcholine; or,
after prolonged treatment with β-agonists, by attenuated activity of β2-
adrenoceptors can all contribute to airway obstruction in asthma and
COPD [[1–3],[1–3]]. Alongside anti-inﬂammatory therapies (e.g. in-
haled glucocorticosteroids for asthma), management of both diseases
relies heavily on inhaled drugs that induce relaxation of ASM via sti-
mulation of β2-adrenoceptors (e.g. salbutamol or indacaterol) or an-
tagonists of M3 muscarinic receptors (e.g. glycopyrronium bromide) to
block contraction evoked by endogenous acetylcholine [[1–3],4]. Cur-
rent therapies can provide some symptomatic relief for COPD, but they
fail to prevent disease progression, and there are concerns about long-
term use of β-agonists in asthmatic patients [5].
An increase in intracellular free Ca2+ concentration ([Ca2+]i) sti-
mulates contraction of ASM, but additional mechanisms regulate the
Ca2+-sensitivity of the contractile machinery, notably through RhoA
and inhibition of myosin light chain (MLC) phosphatase [6]. Defects in
Ca2+ signaling and the sensitization pathways are proposed to con-
tribute to airway hyper-responsiveness [7–10]. Ca2+ signals are usually
initiated by receptors that stimulate phospholipase Cβ (PLCβ) and
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thereby formation of inositol 1,4,5-trisphosphate (IP3), which evokes
Ca2+ release from the sarcoplasmic reticulum through IP3 receptors
(IP3R). In human ASM, the major physiological contractile stimulus is
acetylcholine released from parasympathetic terminals, which then
stimulates PLCβ through M3 receptors and Gq/11 [11], and possibly also
through M2 receptors and Gi [12]. In diseased airways, contraction may
be evoked by additional stimuli because the stimuli accumulate within
the airways (e.g. bradykinin and histamine) [1] and/or their receptors
are up-regulated (e.g. B2 bradykinin receptors) [13].
In ASM from various mammals, β-agonists cause relaxation and
attenuate the increase in [Ca2+]i evoked by receptors that stimulate
PLC [5]. The mechanisms are not resolved, but there is evidence for
reduced accumulation of IP3 [14], increased activity of the SR/ER
Ca2+-ATPase (SERCA) [15], and inhibition of IP3Rs [16]. It has been
widely supposed that cAMP and cAMP-dependent protein kinase (PKA)
mediate these eﬀects of β-agonists, but the evidence has been incon-
clusive [see discussion in 5] and there are suggestions that exchange
proteins activated by cAMP (Epacs) may be more important than PKA
[17,18]. Because ASM from diﬀerent species respond to diﬀerent sti-
muli [19] it is important to examine human cells, but there have been
relatively few analyses of Ca2+ signaling in human ASM. The most
informative studies have used either precision-cut lung slices, where the
complex relationships between ASM and associated cells are main-
tained [19]; or cultured ASM, which bring the beneﬁts of simplicity and
availability, but with a risk that phenotypes may change in culture
[20]. Hitherto, a major limitation of cultured human ASM has been loss
of the muscarinic receptors [20,21] that both contribute to the con-
tractile responses in COPD and asthma, and provide important targets
for therapy.
Concern about long-term use of long-acting β-agonists has prompted
interest in alternative therapies for asthma and COPD. These include
prostaglandin E2 (PGE2), which can also stimulate adenylyl cyclase
(AC), primarily through EP2 and EP4 receptors [22]. High concentra-
tions of PGE2 are found in human lower respiratory tract [23] and they
are increased further in eosinophilic bronchitis [24]. PGE2 relaxes
human airways [22]; EP2 and EP3 receptors are upregulated in ASM
from asthmatic patients [25]; and inhaled PGE2 may beneﬁt patients
with asthma or chronic bronchitis [22]. However, species diﬀer in the
responses of their ASM to PGE2 and in the EP receptors they express
[22,26]. Even within human airways, there is conﬂicting evidence for
the relative contributions of EP2 [27] and EP4 [22] receptors to relaxant
responses. The eﬀects of PGE2 on the Ca2+ signals evoked by contractile
stimuli in human ASM are unknown. There is, therefore, a need in
human ASM to establish whether PGE2 aﬀects Ca2+ signals and through
which receptors. Furthermore, there is evidence that β-agonists and
PGE2 stimulate diﬀerent isoforms of AC, thereby producing cAMP in
diﬀerent intracellular locations and with diﬀerent functional con-
sequences [see references in 28]. Hence, there is a need to determine in
human ASM the interplay between the diﬀerent G protein-coupled re-
ceptors (GPCRs) that stimulate Ca2+ and cAMP signals.
2. Methods
2.1. Materials
FLIPR calcium 4 assay kit was from Molecular Devices (Wokingham,
UK). Fluo-4-AM, fura-2-AM and Hank's balanced salt solution (HBSS)
with Ca2+ and Mg2+ were from Life Technologies (Paisley, UK). BAPTA
was from Molekula (Dorset, UK). Ultragold scintillant and [2,8-3H]
adenine were from Perkin Elmer (Buckinghamshire, UK). Ionomycin
was from Apollo Scientiﬁc (Stockport, UK). Smooth muscle growth
medium 2 (SMGM-2) and supplement were from Promocell
(Heidelberg, Germany). Pertussis toxin (PTX) was from List Biological
Laboratories (Campbell, CA, USA). Histamine dihydrochloride, carba-
mylcholine chloride (carbachol), (−)-isoproterenol hydrochloride,
PGE2, 3-isobutyl-1-methylxanthine (IBMX), bradykinin acetate, Dowex
50WX4-400, alumina, imidazole, probenecid, anhydrous dimethyl
sulfoxide (DMSO), pluronic F127, triton-X-100, poly-L-lysine, 8-Br-
cAMP, 8-Br-cGMP, dibutyryl cAMP, KT5720 ((9R,10S,12S)-2,3,9,10,
11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo
[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic
acid, hexyl ester), GdCl3, nimodipine, 2-aminoethoxyphenylborane
(2-APB), ATP and acetonitrile were from Sigma (Poole, UK). 18:1
lysophosphatidic acid (LPA) was from Avanti Polar Lipids (Alabaster,
AL, USA). 8-pCPT-2′-O-Me-cAMP, ESI-05 (4-methylphenyl-2,4,6-
trimethylsulphone), Rp-8-CPT-cAMPs and 6-Bnz-cAMP were from
Biolog (Bremen, Germany). TCS2510 ((5R)-5-[(3S)-3-hydroxy-4-
phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5-yl)hexyl]-2-pyrrolidinone),
H89 dihydrochloride (N-[2-[[3-(4-bromophenyl)-2-propenyl]amino]
ethyl]-5-isoquinolinesulfonamide dihydrochloride), myristoylated pro-
tein kinase inhibitor 14–22 amide (PKI-myr), ryanodine, trans-Ned-19
and edelfosine were from Tocris/Biotechne (Minneapolis, MN, USA).
Sulprostone was from Enzo Life Sciences (Exeter, UK). R-butaprost (free
acid), NKH477 (N,N-dimethyl-(3R,4aR,5S,6aS,10S,10aR,10bS)-5-(acet-
yloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-penta-
methyl-1-oxo-1H-naphtho[2,1-b]pyran-6-yl ester β-alanine hydro-
chloride) and forskolin were from Cayman Chemicals (Ann Arbor, MI,
USA). When DMSO or ethanol was used as a solvent, all related assays
included solvent at the same ﬁnal concentration; neither solvent, at the
highest concentrations used, aﬀected biological responses.
2.2. Culture of hBASMCs
Human bronchial ASM cells (hBASMC, passage 3) from three male
donors (aged 11, 4 and 37 years, donors 1–3, respectively) were from
Lonza (catalogue number CC-2576, Basel, Switzerland). The cells had
been isolated from the major bronchi of undiseased tissue and shown to
stain for α-smooth muscle actin, but not for von Willebrand Factor VIII.
Cells were grown in SMGM-2 (Lonza) supplemented with fetal calf
serum (5%, Sigma), and recombinant human forms of epidermal
growth factor (0.5 ng·mL−1), basic ﬁbroblast growth factor (2 ng·mL−1)
and insulin (5 μgmL−1) (all from Promocell, Heidelberg, Germany).
Cells were grown at 37 °C in humidiﬁed air containing 5% CO2, and
passaged when they were 80–90% conﬂuent. Cells from passages 4–10
were used for experiments. There were no obvious changes in mor-
phology, growth rate or signaling responses within this range of pas-
sages.
2.3. Measurements of [Ca2+]i in populations of hBASMCs
Two methods were used to measure [Ca2+]i in populations of
hBASMCs. For measurements using a FlexStation III plate-reader
(Molecular Devices, Sunnyvale, CA, USA), hBASMCs were seeded into
96-well plates (104 cells per well). After about 4 days, when the cells
were conﬂuent, the medium was replaced with SMGM-2 without serum
or growth factor supplements, and the cells were used after a further
24 h. This period in serum-free medium increased by about 2-fold the
amplitude of the increases in [Ca2+]i evoked by histamine (results not
shown). Cells were washed with HEPES-buﬀered saline (HBS: 135mM
NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 1.5mM CaCl2, 11.6mM HEPES,
11.5 mM D-glucose, pH 7.3), and loaded with ﬂuo-4 by incubation with
ﬂuo-4-AM (2 μM) in HBS (100 μL per well) containing pluronic F127
(0.02%, v/v) and probenecid (2.5 mM). After 1 h at 20 °C, the medium
was replaced with HBS (100 μL per well) containing probenecid
(2.5 mM). After a further incubation at 20 °C for 1 h, the medium was
replaced with HBS (60–80 μL per well) or nominally Ca2+-free HBS,
and the cells were used immediately for experiments at 20 °C. In some
experiments, BAPTA (2.5mM) was added to HBS during the recording;
this reduced the free [Ca2+] of the HBS to ∼120 nM without aﬀecting
the pH. Drug additions (20 μL at 4 or 5 times the ﬁnal concentration)
were added automatically. Fluorescence from ﬂuo-4 (excitation
485 nm, emission 525 nM) was recorded at 1.44-s intervals using
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Softmax Pro 5.4 (Molecular Devices). Fluorescence was calibrated to
[Ca2+]i from:












where, KDCa is the equilibrium dissociation constant of ﬂuo-4 for Ca2+
(345 nM) [29], F is the recorded ﬂuorescence, and Fmin and Fmax are the
ﬂuorescence values recorded after addition of triton-X-100 (0.1%, v/v)
with either BAPTA (10mM, Fmin) or CaCl2 (10mM, Fmax). Although
treatment with triton-X-100 releases ﬂuo-4 from cells into the medium,
the ﬂuo-4 ﬂuorescence is captured with the same eﬃciency whether it
is trapped within cells or dispersed within the small volume of the wells
(unpublished observations). Fmax was determined for each well at the
end of an experiment, and the average value was used for each column
of 8 wells. Fmin was determined from parallel wells on each plate.
For measurements of [Ca2+]i using an FDSS 7000 FLIPR
(Hamamatsu), hBASMCs were seeded into 384-well plates (8000 cells
per well) in 20 μL of SMGM-2 containing 5% serum. After 24 h, the
medium was replaced with 15 μL of serum-free SMGM-2, and after a
further 6 h the cells were loaded with Ca2+ indicator by addition of
FLIPR calcium 4 assay kit (Molecular Devices) supplemented with
probenecid (2.5 mM). The exact composition of this ‘no-wash’ indicator
kit is not disclosed by the manufacturer, but it contains ﬂuo-4-AM and
components that reduce background ﬂuorescence. The manufacture’s
stock solution was diluted 10-fold into HBSS containing BSA (0.1%, w/
v) and HEPES (20mM); 5 μL of this solution was then added to each
well (containing 15 μL of serum-free SMGM-2). After 2 h at 37 °C in
humidiﬁed air containing 5% CO2, the plate was used for experiments
at 20 °C. Most additions (5 μL) were prepared in HBSS supplemented
with HEPES (20mM) and BSA (0.1%, w/v). For more prolonged in-
cubations, drugs were diluted in the initial loading medium (to avoid
changes in dye-loading during the ‘no wash’ protocol). Fluorescence
signals (excitation at 480 nm, emission at 540 nm) were calibrated to
[Ca2+]i after measurement of Fmin and Fmax uniquely for each well,
using a KDCa =345 nM.
All concentration-eﬀect relationships were determined by addition
of diﬀerent drug concentrations to individual wells in the same multi-
well plate, rather than by sequential additions to the same well.
2.4. Measurements of intracellular cAMP by [3H]-adenine labeling
hBASMCs in 24-well plates (50,000 cells per well) were grown to
conﬂuence. The medium was then replaced with serum-free SMGM-2,
and after 24 h this was supplemented with [3H]-adenine (1 μCi per well,
18.4 Ci·mmol−1). After 2 h at 37 °C in humidiﬁed air with 5% CO2, the
medium was removed, and the cells were washed twice with HBS. The
cells were stimulated at 20 °C in HBS. Incubations were terminated by
removal of the medium, addition of ice-cold trichloroacetic acid (5%,
1mL) and rapid freezing. This protocol ensured that only intracellular
[3H]-cAMP was detected. [3H]-adenine nucleotides were separated by
column chromatography [30], and the activity was determined by li-
quid scintillation counting using Ultra-gold scintillant. Results are
presented as [3H]-cAMP activity as a percentage of the sum of the ac-
tivities of the fractions containing [3H]-cAMP, [3H]-ATP, [3H]-ADP and
[3H]-AMP; henceforth, reported as [3H]-cAMP (%).
2.5. Measurements of intracellular cAMP by mass spectrometry
These methods were modiﬁed from [31]. Conﬂuent cultures of
hBASMCs in 48-well plates were serum-deprived (6–24 h) and the
medium was then replaced with HBSS (300 μL) containing HEPES
(5mM) and BSA (0.1%, w/v). Cells were stimulated at 20 °C, and re-
actions were terminated by aspiration of the medium and addition of
acetonitrile (170 μL) containing dibutyryl cAMP (0.5 μM, to provide an
internal standard). The plates were centrifuged (1500 xg, 15min, 4 °C),
supernatants (158 μL) were transferred to a 96-well, glass-coated plate
(Thermo Scientiﬁc), and aqueous NH4HCO3 (pH 9.4, 93 μL) was added
to each sample. After mixing and centrifugation (1500 xg, 15min, 4 °C),
samples were stored at 4 °C before analysis.
Samples were analyzed by liquid chromatography tandem mass
spectrometry (LC–MS/MS) using a Waters Acquity UPLC and a Sciex
5500 mass spectrometer equipped with an electrospray ionization
source. ATP, ADP, AMP and cAMP were analyzed using a ZIC-pHILIC
polymeric column (5-μm particle size, 5.0× 2.1mm) maintained at
35 °C. Calibration standards were prepared in the lysis medium con-
taining the internal standard, dibutyryl cAMP (0.5 μM). The injector
was maintained at 4 °C and injection volumes were 5 μL. The mobile
phase comprised solvents A (20% acetonitrile, 80% aqueous NH4HCO3,
pH 9.4) and B (100% acetonitrile). The mobile phase (0.4 mL·min−1)
was 40% A (0.2min), then a linear gradient from 40% to 100% A
(0.8min), followed by 100% A (1min). The gradient was returned to
the initial conditions over 0.5min, and maintained for a further
1.5 min. Samples were detected using multiple reaction monitoring in
negative ion mode using the following parent-to-daughter mass tran-
sitions: cAMP m/z 327.9→ 133.9 (DP −100 V, CE −33 eV), AMP m/z
345.9→ 134.0 (DP −100 V, CE −50 eV), ADP m/z 426.0→ 134.0 (DP
−100 V, CE −30 eV), ATP m/z 505.9→ 408.0 (DP −100 V, CE
−35 eV), and internal standard dibutyryl cAMP m/z 468.1→ 175.0 (DP
−100 V, CE −35 eV).
2.6. Data and statistical analysis
Concentration-eﬀect relationships were ﬁtted to logistic equations
for each experiment using GraphPad Prism (version 5, GraphPad
Software, La Jolla, CA, USA), from which half-maximally eﬀective drug
concentrations (EC50), maximal responses, and Hill slopes were de-
termined. For statistical analyses, maximal responses, Hill slopes and
pEC50 (-logEC50) or pIC50 (-log of the half-maximal inhibitory con-
centration, IC50) values determined for individual experiments were
pooled for statistical analysis. Two-tailed Student’s t-tests or one-way
ANOVA with Bonferroni’s or Dunnett’s multiple comparison tests were
used as appropriate. P< 0.05 was considered signiﬁcant. Results are
reported as mean ± SEM with n indicating the number of independent
experiments (ie performed with diﬀerent culture plates on diﬀerent
days, and usually with all reagents independently prepared). Most
statistical analyses used GraphPad Prism (version 5).
3. Results
3.1. GPCRs evoke Ca2+ signals in hBASMCs through IP3Rs
Stimuli of several GPCRs reported to be expressed in ASM evoked
increases in [Ca2+]i in hBASMCs (Fig. 1A). Cells from all three donors
responded to histamine, LPA and bradykinin, but cells from only one
donor responded robustly to ATP (donor 3) and cells from only one
other donor responded robustly to carbachol (donor 2) (Fig. 1A). The
response to carbachol was unexpected because although native
hBASMCs express M2 and M3 muscarinic receptors [12], their expres-
sion is usually lost when cells are cultured (see Section 1). Our identi-
ﬁcation of functional muscarinic receptors provides the ﬁrst opportu-
nity to examine the eﬀects of the most important physiological stimulus
for contraction in cultured hBASMCs.
The peak increases in [Ca2+]i evoked by histamine, bradykinin or
carbachol were unaﬀected by removal of extracellular Ca2+, con-
ﬁrming that the initial response was entirely mediated by release of
Ca2+ from intracellular stores (Fig. 1B). The responses were also un-
aﬀected by block of L-type Ca2+ channels with nimodipine (Fig. 1C). In
a parallel experiment with single fura-2-loaded hBASMCs, replacing
extracellular Na+ with K+ (140mM) to evoke depolarization caused a
detectable increase in [Ca2+]i in 29 of 44 cells (from a single experi-
ment). This response was reversibly inhibited by nimodipine (10 μM,
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5min): the peak increase in [Ca2+]i recorded from all 44 cells was
50 ± 11 nM and 20 ± 14 nM in the absence and presence of nimo-
dipine, respectively (mean ± SD from a single experiment, P < 0.05,
Student’s t-test). Neither ryanodine to inhibit ryanodine receptors (RyR)
(Fig. 1D) nor trans Ned-19 to inhibit two-pore channels (TPC) [32,but
see reference 33] (Fig. 1C) substantially aﬀected the Ca2+ signals
evoked by histamine, bradykinin or carbachol, although the sensitivity
to histamine was slightly reduced by both inhibitors. The concentra-
tions of the inhibitors used were shown by others to eﬀectively inhibit
their targets [see references in 34] A lack of response to caﬀeine (data
Fig. 1. GPCRs stimulate increases in [Ca2+]i in hBASMCs through activation of PLC and IP3Rs. A, Populations of ﬂuo-4-loaded hBASMCs in 384-well plates were stimulated with the
indicated drug concentrations in HBSS. Peak increases in [Ca2+]i are shown (Δ[Ca2+]i) as means ± SEM for cells from donors 1, 2 and 3 (n=4, 3 and 3, respectively). B, Eﬀects of
histamine, bradykinin and carbachol on Δ[Ca2+]i and the sensitivity to each (pEC50) in either HBS or Ca2+-free HBS (2.5 mM BAPTA added 37 s before the stimulus). Cells were from
donor 1 for histamine and bradykinin (n=3) and from donor 2 for carbachol (n=4). C, D, Eﬀects of nimodipine (10 μM, 5min), trans Ned-19 (1 μM, 5min) or ryanodine (50 μM, 5min)
on the Ca2+ signals evoked by the indicated stimuli in HBSS. Results (B-D) show means ± SEM, n=7 (histamine, donor 1), n=4 (bradykinin, donor 1) and n=3 (carbachol, donor 2).
*P< 0.05, one-way repeated ANOVA with Dunnett’s test (C) or paired two-tailed Student’s t-test (D), each relative to control. E, Eﬀects of pre-incubation (30min) with the indicated
concentrations of edelfosine on basal [Ca2+]i and the peak increases in [Ca2+]i evoked by carbachol (10 μM). Results (mean ± SEM, n=3) are from donor 2. F, Eﬀects of the indicated
concentrations, of 2-APB added 5min before histamine (10 μM, n=7), carbachol (10 μM, n=3) or bradykinin (1 nM, n=4) in HBSS, or to ionomycin (1 μM, n=7) added in Ca2+-free
HBSS to determine the Ca2+ content of the intracellular stores. Results are from donors 1 and 2.
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not shown) and the insensitivity of most responses to ryanodine
(Fig. 1D) may reﬂect a loss of functional RyRs during culture of
hBASMCs, as noted previously for other smooth muscle cells [34].
However, even in human lung slices, which do express RyRs, histamine-
evoked Ca2+ signals were unaﬀected by inhibition of RyRs [19].
Edelfosine, an inhibitor of PLC [35], caused a concentration-de-
pendent inhibition of the responses evoked by carbachol (Fig. 1E),
histamine and bradykinin. The pIC50 values for inhibition by edelfosine
of the Ca2+ signals evoked by histamine (10 μM), bradykinin (1 nM)
and carbachol (10 μM) were 4.64 ± 0.13, 4.47 ± 0.06 and
4.40 ± 0.04, respectively (n=3). There are no selective and eﬀective
membrane-permeant inhibitors of IP3Rs [36]. 2-APB inhibits IP3Rs, but
it also modulates store-operated Ca2+ entry, and it inhibits the Ca2+
pump that mediates Ca2+ uptake into the ER [37]. The results shown in
Fig. 1F demonstrate that under conditions where Ca2+ entry does not
contribute to the GPCR-evoked Ca2+ signals (Fig. 1B), 2-APB abolished
the increases in [Ca2+]i evoked by histamine, bradykinin and carba-
chol. 2-APB also reduced the Ca2+ content of the intracellular stores
(assessed by addition of ionomycin in Ca2+-free HBS), but this eﬀect
was less substantial and required higher concentrations of 2-APB than
the inhibition of GPCR-evoked Ca2+ signals (Fig. 1F).
Pre-treatment of hBASMCs with pertussis toxin (PTX) had no eﬀect
on the Ca2+ signals evoked by histamine or bradykinin, but it
signiﬁcantly reduced both the maximal amplitude of the Ca2+ signals
evoked by carbachol and LPA and their sensitivity to these stimuli
(Fig. 2). The incomplete block of responses to carbachol and LPA by
PTX is unlikely to result from incomplete modiﬁcation of Gi proteins,
because in parallel experiments the same treatment with PTX abolished
the inhibition of AC activity by carbachol, probably acting via M2
muscarinic receptors [12] (data not shown).
The results so far demonstrate that histamine, bradykinin, carba-
chol, ATP and LPA can evoke Ca2+ signals in hBASMCs. The initial
responses are likely to be mediated by Ca2+ release through IP3Rs after
stimulation of PLCβ by Gq/11. In addition, release of Gβγ subunits from
Gi contributes to responses evoked by carbachol, and more so to the
Ca2+ signals evoked by LPA. The results with carbachol are consistent
with evidence from human lung tissue showing that M3 receptors
mediate most carbachol-evoked contraction, with lesser [12] or un-
detectable [38] contributions from M2 receptors.
3.2. Isoproterenol inhibits histamine-evoked Ca2+ signals through cAMP
and PKA
Activation of β-adrenoceptors with isoproterenol stimulated a con-
centration-dependent accumulation of intracellular cAMP within
hBASMCs (Fig. 3A). Isoproterenol also inhibited histamine-evoked
Fig. 2. Pertussis toxin selectivity attenuates the Ca2+
signals evoked by LPA and carbachol. A-D, Eﬀects of
pre-treatment with pertussis toxin (PTX, 100
ng·mL−1, 24 h) on the peak increases in [Ca2+]i
evoked by the indicated stimuli. Results are from
cells derived from donors 1 and 2 (n=3 for B and C;
n=4 for A and D). E, F, Summary results.
*P < 0.05, paired Student’s t-test, relative to con-
trol.
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Ca2+ signals by signiﬁcantly reducing both the maximal amplitude of
the peak increase in [Ca2+]i (from 242 ± 15 nM to 168 ± 19 nM,
n=7) and the sensitivity to histamine (pEC50= 5.98 and 5.37)
(Fig. 3B, C). Histamine-evoked Ca2+ signals were more sensitive to
isoproterenol (pIC50= 8.09 ± 0.21, n=4) than was cAMP accumu-
lation (pEC50= 6.88 ± 0.39, n=3) (Fig. 3A, D).
The inhibition of histamine-evoked Ca2+ signals by isoproterenol
was mimicked by a membrane-permeant analogue of cAMP, 8-Br-cAMP
(pIC50= 3.32 ± 0.16, n=6), but not by 8-Br-cGMP (Fig. 4A). In-
hibition of cyclic nucleotide phosphodiesterases with IBMX also caused
an accumulation of intracellular cAMP and an inhibition of histamine-
evoked Ca2+ signals (Fig. 4B). Direct activation of AC by forskolin
(Fig. 4C) or its more water-soluble analogue NKH477 (Fig. 4D) also
mimicked the eﬀect of isoproterenol. Neither isoproterenol nor for-
skolin (10 μM, 5min) aﬀected the Ca2+ content of the intracellular
stores, assessed by addition of ionomycin in Ca2+-free HBS (results not
shown). The maximal inhibitory eﬀects of forskolin and isoproterenol
on histamine-evoked Ca2+ signals were similar and no larger with both
stimuli together (Fig. 4C), although their combined eﬀects on cAMP
accumulation were larger than with either stimulus alone (Fig. 4C, E).
These results suggest that either stimulus can evoke formation of more
cAMP than needed to maximally inhibit the histamine-evoked Ca2+
signals, consistent with our evidence that the inhibition of Ca2+ signals
is more sensitive than the formation of cAMP to isoproterenol (Fig. 1A
and 3D). These results are consistent with cAMP preceding inhibition of
Ca2+ signals in the signaling pathway [39], and with maximal activa-
tion by isoproterenol generating more cAMP than required to maxi-
mally inhibit the Ca2+ signals. Our results conﬁrm those from human
lung slices, where histamine-evoked Ca2+ signals and contractions
were attenuated by formoterol [19], and they extend them by demon-
strating that the eﬀects of β2-adrenoceptors are entirely mediated by
cAMP.
While our work was in progress, the ﬁrst direct evidence conﬁrming
a role for PKA in mediating the eﬀects of β2-adrenoceptors on Ca2+
signals and relaxation of cultured smooth muscle from human trachea
and bronchi was published [5]. The authors demonstrated that stable
expression of a peptide inhibitor of PKA (PKI) abolished the inhibition
of histamine-evoked Ca2+ signals by isoproterenol, knockdown of
Epacs 1 and 2 had no eﬀect on the inhibition by isoproterenol of the
histamine-stimulated phosphorylation of myosin light chain 2, and nor
did an Epac-selective cAMP analogue mimic the eﬀect of isoproterenol.
Our results are consistent with their conclusion that Epacs do not
contribute to the inhibition of histamine-evoked Ca2+ signals by iso-
proterenol. Pre-treatment of hBASMCs with a cAMP analogue selective
for PKA, 6-Bnz-cAMP (500 μM, 20min) [40], reduced the amplitude of
the Ca2+ signals evoked by histamine (10 μM) to 54 ± 4% of these
recorded from paired controls (n=5), whereas the Epac-selective
analog 8-pCPT-2′-O-Me-cAMP (300 μM) had no eﬀect (103 ± 8%).
Two of the commonly used antagonists of Epacs (ESI-09 and HJC0197)
[41] have intolerable oﬀ-target eﬀects [42,43]. However, an Epac-2
inhibitor, ESI-05 [41], had no eﬀect on the concentration-dependent
inhibition of histamine-evoked Ca2+ signals by isoproterenol (Figs.
Fig. 4F and Fig. 5A). Our results with inhibitors of PKA, in keeping with
similar published approaches [44], were inconclusive (Fig. 5A). In-
hibitors expected to interact with the ATP-binding site of PKA (H89 and
KT5720), its cAMP-binding site (Rp-8-CPT-cAMPS) or its peptide-
binding site (PKI-myr) had no signiﬁcant eﬀect on the inhibition of
histamine-evoked Ca2+ signals by a maximally eﬀective concentration
of isoproterenol (Fig. 5A). H89 signiﬁcantly reduced the sensitivity to
isoproterenol, but that may be due to it being a competitive antagonist
of β-adrenoceptors [45]. Rp-8-CPT-cAMPS also caused a signiﬁcant
decrease in the sensitivity to isoproterenol, but the eﬀect was small
(Fig. 5A). Neither KT5720 nor PKI-myr signiﬁcantly aﬀected the sen-
sitivity to isoproterenol. Both we and others have failed to achieve ef-
fective inhibition of PKA in intact smooth muscle cells with these in-
hibitors [[5],43,44]. However, in light of the recently published work
Fig. 3. Inhibition of histamine-evoked Ca2+ signals by isoproterenol. A, Eﬀects of iso-
proterenol (5 min) on intracellular cAMP concentrations in hBASMCs. Results are from
MS analyses, n=3. B, Typical traces from populations of ﬂuo-4-loaded hBASMCs sti-
mulated in HBS with histamine alone (10 μM, black trace) or after pre-incubation with
isoproterenol (10 μM, 5min, red trace) (n=6). C, Summary results from similar ex-
periments performed in HBSS (n=7) show Δ[Ca2+]i evoked by histamine alone or after
treatment with isoproterenol. D, Concentration-dependent eﬀects of isoproterenol (added
5min before histamine) on Δ[Ca2+]i evoked by histamine (10 μM) in HBSS. Results, are
expressed as percentages of the matched control response without isoproterenol (n=4).
Results are from donor 1 (A, C and D) or donors 1 and 2 (B).
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we suggest that PKA probably mediates most relaxant eﬀects of iso-
proterenol in human ASM [5] and it is therefore likely also to mediate
the eﬀects of isoproterenol on histamine-evoked Ca2+ signals. That
conclusion is also consistent with recent analyses of human aortic
smooth muscle, where selective inhibition of histamine-evoked Ca2+
signals by PGE2 was shown to be mediated by PKA [43].
3.3. Isoproterenol signals to Ca2+ signals through compartmentalized cAMP
During sustained incubation with isoproterenol, cAMP continued to
accumulate for at least 30min, such that the stimulated cAMP con-
centration was 2.8-fold higher after 30min than after 1min (Fig. 5Bi).
However, the inhibition of Ca2+ signals was similar when hBASMCs
were pre-incubated with isoproterenol for intervals between 1 and
30min before addition of histamine (Fig. 5Bii, Biii). Hence, even
though cAMP continued to accumulate long after the ﬁrst minute of
stimulation with isoproterenol, neither the maximal inhibition of his-
tamine-evoked Ca2+ signals nor their sensitivity (pIC50) to iso-
proterenol was increased by prolonging the incubation (Fig. 5B). Since
maximal activation of β2-adrenoceptors provides more cAMP than
needed to maximally inhibit histamine-evoked Ca2+ signal, it is un-
surprising that prolonged incubation with a maximally eﬀective con-
centration of isoproterenol caused no further inhibition of Ca2+ signals.
However, when cAMP entirely mediates the eﬀects of isoproterenol
(Fig. 4), it is surprising that the sensitivity of histamine-evoked Ca2+
signals to isoproterenol is unaﬀected by prolonged incubations during
Fig. 4. Isoproterenol inhibits histamine-evoked Ca2+
signals through cAMP. A, Peak increases in [Ca2+]i
evoked by histamine (10 μM) after pre-treatment
with the indicated concentrations of 8-Br-cAMP or 8-
Br-cGMP (20min) (n=4). B, Eﬀects of the indicated
concentrations of IBMX (20min) on the intracellular
concentration of cAMP (measured by MS) and the
peak increase in [Ca2+]i evoked by histamine
(10 μM). Results are expressed as percentages of the
Δ[Ca2+]i evoked by histamine alone (n=6, donor 1)
or as percentages of the cAMP concentration de-
termined with the maximal concentration of IBMX
(1mM) (n=5, donor 1). C, Eﬀects of pre-incubation
(30 min) with isoproterenol (10 μM), forskolin
(10 μM) or both on the peak increase in [Ca2+]i
evoked by histamine in HBSS, and their sensitivity to
histamine (pEC50) (donor 1, n=4). Parallel experi-
ments show eﬀects of the same treatments on in-
tracellular cAMP accumulation determined after 3H-
adenine-labeling of cells in HBS (donor 1, n=3).
*P < 0.05, one-way repeated measures ANOVA with
Dunnett’s test, relative to response evoked in the
presence of isoproterenol. D, Peak increases in
[Ca2+]i evoked by the indicated concentrations of
histamine in HBS after pre-treatment (5 min) with
solvents (DMSO or EtOH), isoproterenol (10 μM),
NKH477 (10 μM), TCS 2510 (1 μM) or butaprost
(10 μM) (n=4). E, Intracellular cAMP accumulation
in hBASMCs stimulated for 5min in HBS with
NKH477 (10 μM), forskolin (10 μM), isoproterenol
(10 μM), PGE2 (10 μM), TCS 2510 (1 μM) or buta-
prost (10 μM). Results ([3H]-cAMP, %, see Methods)
are from donor 1 (n=6-8), but were conﬁrmed in
donor 2. *P < 0.05, one-way repeated measures
ANOVA with Dunnett’s test, relative to basal. F,
Eﬀects of ESI-05 (25 μM, 30min) in HBS on the Ca2+
signals evoked by histamine (10 μM) added 1min
after the indicated concentrations of isoproterenol.
Results are expressed as percentages of matched re-
sponses to histamine in the absence of isoproterenol
(donors 1 and 2, n=9).
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which more intracellular cAMP accumulates (Fig. 5B). Inhibition of
Ca2+ signals by β2-adrenoceptors cannot, therefore, be mediated by
cAMP uniformly distributed throughout the cytosol.
Whereas GPCRs may locally deliver cAMP at high concentrations to
targets within signaling junctions [28 and references therein], this is
less likely for cAMP accumulated after addition of IBMX, a non-selec-
tive inhibitor of cyclic nucleotide phosphodiesterases (Fig. 4B). We
therefore compared the relationship between intracellular cAMP and
inhibition of histamine-evoked Ca2+ signals, for cAMP responses
evoked by IBMX or isoproterenol. For matched Ca2+ signals, the in-
hibition evoked by isoproterenol was associated with∼5.4-fold higher
concentrations of intracellular cAMP than for IBMX (Fig. 5C). These
results again suggest that histamine-evoked Ca2+ signals are not
regulated by globally distributed cAMP.
3.4. PGE2 inhibits histamine-evoked Ca2+ signals through both EP2 and EP4
receptors
In hBASMCs, PGE2 stimulated cAMP accumulation (Fig. 4E) but,
unlike isoproterenol or forskolin, PGE2 directly evoked a signiﬁcant
increase in [Ca2+]i (Fig. 6A). This response was probably mediated by
EP3 receptors because sulprostone, a selective agonist of Gi-coupled EP3
receptors [46], also evoked an increase in [Ca2+]i (Fig. 6B).
In subsequent experiments, butaprost and TCS2510 were used to
selectively stimulate EP2 and EP4 receptors, respectively. Both receptors
are known to stimulate Gs and thereby AC activity [47,48]. Neither
butaprost nor TCS2510 evoked an increase in [Ca2+]i (results not
shown), but both stimulated formation of cAMP and inhibited the Ca2+
signals evoked by histamine (Fig. 4D, E). Although a maximal con-
centration of TCS2510 was as eﬀective as forskolin, NKH477, iso-
proterenol or butaprost in inhibiting histamine-evoked Ca2+ signals, it
evoked far less production of cAMP (Fig. 4E). This suggests that max-
imal activation of EP2 receptors (by butaprost), like maximal activation
of β-adrenoceptors (by isoproterenol), evokes formation of more cAMP
than needed to cause maximal inhibition of histamine-evoked Ca2+
signals. Our results are consistent with evidence that human ASM ex-
press EP2, EP3 and EP4 receptors, that EP3 receptors evoke an increase
in [Ca2+]i, that both EP2 and EP4 receptors stimulate accumulation of
cAMP [26], and with recent evidence showing that EP2 receptors evoke
local cAMP signals in human ASM [28]. PGE2 causes relaxation of
histamine-contracted human airways, but conﬂicting reports have
suggested that this is mediated entirely through EP2 [27] or EP4 re-
ceptors [22]. Our results provide the ﬁrst evidence that both EP2 and
EP4 receptors inhibit histamine-evoked Ca2+ signals in human ASM.
3.5. Ca2+ signals evoked by diﬀerent GPCRs diﬀer in their susceptibility to
inhibition by cAMP
Fig. 6C–F compares the eﬀects of activating AC directly (with for-
skolin) or via Gs-coupled GPCRs (β2-adrenoceptors, EP2 or EP4 re-
ceptors) on the Ca2+ signals evoked by histamine, LPA, bradykinin or
carbachol in hBASMCs. The results conﬁrm the substantial inhibition of
histamine-evoked Ca2+ signals by cAMP, but the Ca2+ signals evoked
by carbachol and bradykinin were unaﬀected by any of the cAMP-ele-
vating stimuli. Analyses of single fura 2-loaded cells conﬁrmed that all
cells responded to both histamine and bradykinin with an increase in
Fig. 5. Compartmentalized cAMP inhibits histamine-
evoked Ca2+ signals. A, Eﬀects of pre-treatment
(30 min) with the indicated inhibitors and then iso-
proterenol (1 min) on the Ca2+ signals evoked by
histamine (10 μM). Results (donors 1 and 2, n=9)
show the peak Ca2+ signals (as percentages of mat-
ched responses to histamine without isoproterenol)
and their sensitivity to inhibition by isoproterenol
(pIC50). *P < 0.05, one-way repeated measures
ANOVA with Dunnett’s test, relative to control. B,
Eﬀects of varying the duration of the incubation with
isoproterenol (10 μM) on cAMP accumulation (i) and
the peak Ca2+ signals evoked by histamine (10 μM)
(ii and iii). Accumulation of intracellular cAMP was
measured after 3H-adenine labeling ([3H]-cAMP, %).
Results for Δ[Ca2+]i show the peak response as a
percentage of that evoked by histamine alone (ii) and
the pIC50 value for isoproterenol (iii). (n=4). C,
Relationship between intracellular cAMP (de-
termined by MS) and the inhibition of Ca2+ signals
evoked by histamine (10 μM) in cells where the in-
crease in cAMP was evoked by incubation with dif-
ferent concentrations of IBMX (20min) or iso-
proterenol (5 min). Each point includes data from 5
(IBMX) or 3 (isoproterenol) MS determination of
cAMP associated with 6 (IBMX) or 4 (isoproterenol)
measurements of [Ca2+]i. Results (B and C) are from
cells from donor 1.
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[Ca2+]i (results not shown). The diﬀerential susceptibility of the Ca2+
signals evoked by histamine and bradykinin to inhibition by cAMP is
not therefore due to diﬀerential distribution of their receptors between
cells.
Activation of M2 receptors by carbachol might, via Gi, have coun-
teracted the increases in cAMP evoked by forskolin or the Gs-coupled
GPCRs [12,38]. However, the Ca2+ signals evoked by carbachol or
bradykinin remained insensitive to isoproterenol after treatment with
pertussis toxin (Fig. 6G, H). Parallel experiments demonstrated that the
treatment with PTX was suﬃcient to abolish the inhibition of AC ac-
tivity by carbachol (results not shown) and to attenuate the Ca2+ sig-
nals evoked by carbachol and LPA (Fig. 2C-F). These results demon-
strate that cAMP selectively inhibits the Ca2+ signals evoked by
histamine.
4. Discusssion
Our analyses of hBASMCs show that histamine evokes cytosolic
Ca2+ signals by stimulating PLC and release of Ca2+ through IP3Rs
(Fig. 1A–D). Similar mechanisms probably underlie the Ca2+ signals
evoked by carbachol, bradykinin and LPA (Fig. 1B–D). The four stimuli
do, however, diﬀer in the extent to which they regulate PLC exclusively
through Gq/11 (histamine and bradykinin) or with some contribution
from Gi (LPA, and to a lesser extent carbachol) (Figs. 2, 6G, H and 7A).
These results concur with those from human lung slices, where con-
tractions evoked by carbachol or histamine were substantially atte-
nuated by inhibitors of Gq/11 [49], although the speciﬁcity of one of the
inhibitors (UBO-QIC) has been challenged [50].
The Ca2+ signals evoked by histamine were attenuated by
Fig. 6. Ca2+ signals evoked by diﬀerent GPCRs diﬀer
in their susceptibility to inhibition by cAMP. A, Peak
increases in [Ca2+]i evoked by isoproterenol
(10 μM), PGE2 (10 μM) or forskolin (10 μM) in Ca2+-
free HBS (n=7 from donors 1 and 2). *P < 0.05,
one-way ANOVA with Dunnett's test, relative to
control. B, Peak increases in [Ca2+]i evoked by PGE2
or sulprostone in Ca2+-free HBS (BAPTA added 37 s
before the stimuli) (n=3 from donors 1 and 2). C-F,
hBASMCs in HBS were pre-treated (5min) with iso-
proterenol (10 μM), forskolin (10 μM), butaprost
(10 μM), TCS2510 (1 μM) or solvents, and then sti-
mulated with the indicated concentrations of hista-
mine (C), bradykinin (D), carbachol (E) or LPA (F).
The code in C applies to panels C-F. Results show
peak increases in [Ca2+]i evoked by the ﬁnal sti-
mulus from 6 independent experiments from donors
1 and 2 (C, D and F), and from 3 independent ex-
periments with donor 2 (E). (G, H) Similar analyses
of cells in HBS after treatment with pertussis toxin
(PTX, 100 ng·mL−1, 24 h). The code in G applies also
to H. Results are from 3 independent experiments
from donor 2 (G) and donors 1 and 2 (H).
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stimulation of β2-adrenoceptors, consistent with results from human
lung slices where formoterol caused a long-lasting inhibition of hista-
mine-evoked Ca2+ oscillations [19]. In our analyses, the inhibition was
mimicked by stimulation of EP2 or EP4 receptors, 8-Br-cAMP, direct
activation of AC, or by inhibition of cyclic nucleotide PDEs (Figs. 3–6).
These results and the non-additive inhibition of Ca2+ signals by
maximally eﬀective concentrations of forskolin and isoproterenol
(Fig. 4C) establish that inhibition of histamine-evoked Ca2+ signals by
β2-adrenoceptors is entirely mediated by cAMP. The inhibition is not
mediated by activation of epacs (Fig. 4F and 5A), but our attempts to
demonstrate a need for PKA were thwarted by ineﬀective inhibitors
(Fig. 5A)[for further discussion see [5], 43]. However while our work
was in progress, inhibition of histamine-evoked Ca2+ signals by iso-
proterenol was shown to be prevented by viral infection with a peptide
inhibitor of PKA [5]. Hence, we suggest that in hBASMCs inhibition of
histamine-evoke Ca2+ signals by β-adrenoceptors is entirely mediated
by cAMP and PKA (Fig. 7A).
The inhibition of GPCR-evoked Ca2+ signals by cAMP was selective
for histamine. The Ca2+ signals evoked by bradykinin and carbachol
were insensitive to cAMP, while cAMP caused only a modest and in-
consistent inhibition of responses to LPA (Figs. 6CeH and 7A).
Isoproterenol can cause relaxation of airways in human lung slices
contracted with carbachol [12], but the contractions evoked by mus-
carinic receptors are more resistant to the relaxant eﬀects of β2-adre-
noceptors than the contractions evoked by histamine [38,51–53]. These
results are consistent with our ﬁndings, and suggest that a reduction in
the sensitivity of the contractile apparatus to Ca2+ by cAMP may re-
duce contractions evoked by all contractile stimuli [19], while the re-
sponse to histamine is further reduced by attenuation of the Ca2+ sig-
nals. Selective inhibition of histamine-evoked Ca2+ signals by PKA
suggests a target close to the histamine H1 receptor, and perhaps the
receptor itself [see discussion in reference 43] (Fig. 7A).
Although cAMP entirely mediates the inhibition of histamine-
evoked Ca2+ signals by β2-adrenoceptors, there is no consistent re-
lationship between intracellular cAMP and inhibition of Ca2+ signals
under diﬀerent stimulation conditions (Fig. 5C). This suggests an in-
tracellular compartmentalization of the eﬀective cAMP [28]. The cAMP
produced immediately after activation of β2-adrenoceptors most eﬀec-
tively inhibits Ca2+ signals, but the sensitivity to isoproterenol is un-
changed during sustained stimulation despite further accumulation of
cAMP. This suggests that local regulation of histamine responses must
continue throughout the sustained stimulation, but this is accompanied
Fig. 7. Selective inhibition of histamine-evoked
Ca2+ signals by hyperactive cAMP junctions in
human airway smooth muscle. A, Histamine (Hist),
bradykinin (BK), carbachol (CCh) and LPA through
their respective GPCRs stimulate PLCβ entirely
through Gq/ll or with some contribution from Gi. IP3
then stimulates Ca2+ release through IP3Rs within
the sarcoplasmic reticulum. β2-adrenoceptors or re-
ceptors for PGE2 (EP2 and EP4) stimulate AC and
thereby PKA, which selectively inhibits the Ca2+
signals evoked by histamine, perhaps through phos-
phorylation of H1 histamine receptors by PKA. B,
Cyclic AMP may be delivered to PKA within ‘hyper-
active’ signaling junctions, such that activation of a
junction provides more than enough local cAMP to
saturate the associated PKA. The junction thereby
functions as a robust on-oﬀ switch. Concentration-
dependent responses to β2-agonists are due to re-
cruitment of these digital junctions.
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by diﬀusion of cAMP, which then accumulates in cytoplasmic regions
where it does not eﬀectively inhibit histamine responses (Fig. 5B). This
slow accumulation of ‘ineﬀective’ cAMP would provide an explanation
for our observation that as cAMP accumulates during sustained iso-
proterenol stimulation neither the maximal inhibition of histamine-
evoked Ca2+ signals nor their sensitivity to isoproterenol increases
(Fig. 5B). But why should globally distributed cAMP arising from in-
hibition of cyclic nucleotide PDEs appear more eﬀective than cAMP
delivered from β2-adrenoceptors (Fig. 5C)? We suggested previously
that signaling from AC-coupled GPCRs to eﬀector systems may occur
within ‘hyperactive’ signaling junctions [43,54,55] (Fig. 7B). These, we
propose, serve as digital switches, wherein activation of a junction
generates more cAMP than required to fully activate associated PKA.
The concentration-dependent eﬀects of extracellular stimuli are pro-
posed to arise from recruitment of active junctions, rather than from
graded activity within individual junctions (Fig. 7B). Hence, each
junction would behave as a robust on-oﬀ switch, locally saturating the
neighboring PKA for as long as the GPCR stimulates AC. The beneﬁts of
this mode of signaling include speed, reliability and opportunities for
local targeting of cAMP. Since inhibition of histamine-evoked Ca2+
signals by β2-adrenoceptors is associated with higher overall levels of
intracellular cAMP than comparable inhibition with IBMX (Fig. 5C), we
suggest that hyperactive cAMP signaling junctions mediate the com-
munication between β2-adrenoceptors, PKA and histamine responses
(Fig. 7B).
We conclude that cAMP selectively inhibits the Ca2+ signals evoked
by histamine in hBASMCs. Communication between the GPCRs that
stimulate AC and the PKA that mediates the inhibition occurs within
hyperactive signaling junctions. These junctions, which may be a gen-
eral feature of cAMP signaling, allow rapid, robust and speciﬁc com-
munication between receptors and eﬀectors [43,54,55].
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